The biotechnology sector is experiencing a surge of interest as artificial intelligence (AI) increasingly plays a vital role in supporting drug discovery. AI’s ability to accelerate drug development, reduce costs, and improve outcomes has attracted investors, with predictions that it could lead to the creation of 50 novel drugs worth over $50 billion in sales within a decade.
AI’s potential in the field is evident, with notable examples including the rapid development of COVID-19 mRNA vaccines aided by AI algorithms in designing synthetic mRNA and automating quality control processes. In breast cancer screening, AI-based 3D imaging enhances the detection of invasive breast cancer and reduces radiologists’ workload.
Recognizing the significance of AI, the US Food and Drug Administration reports a notable increase in drug submissions incorporating AI-based components, expecting this trend to accelerate further. However, it is crucial for investors to keep the bottom line in mind. While AI appears to hasten medical breakthroughs, it is often a supporting tool within a broader context of extensive research and development.
For instance, companies like Moderna spent years refining synthetic mRNA and gathering and analyzing data to combat the virus effectively. Certain time-intensive aspects of drug development, such as clinical trials and regulatory filings, are unlikely to be significantly altered by AI, as they require thorough testing and evaluation, which can span many years.
Investing in digital biotech companies leveraging AI for molecule development is possible, but it may take considerable time before therapies reach the market. It is important to note that AI enthusiasm may influence stock performance, even if bringing a therapy to market takes years.
On the other hand, computational tools and methods have made tangible progress in enhancing preclinical drug development, benefiting biotech companies that leverage these resources.
In summary, AI holds significant promise for the future of biotech, facilitating faster drug discovery and enabling targeted treatments for patients. However, the true value of AI-driven companies will be determined by the success of their products, which relies on long-term clinical data. Therefore, approaching AI in biotech with caution is advisable until substantial clinical evidence becomes available.
About Author
